Press Releases

May 12, 2021
Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Read More
May 4, 2021
Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update Read More
May 3, 2021
Protagonist Therapeutics Reports Granting of Inducement Award Read More
April 27, 2021
Protagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical Meeting Read More
March 22, 2021
Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with the U.S. Food & Drug Administration and the European Medicines Agency Read More
March 10, 2021
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Read More
March 3, 2021
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results Read More
March 2, 2021
Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference Read More
February 26, 2021
Protagonist Therapeutics Reports Granting of Inducement Award Read More
February 16, 2021
Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference Read More
January 29, 2021
Protagonist Therapeutics Reports Granting of Inducement Award Read More
January 4, 2021
Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Read More